CRITICAL ANALYSIS OF THE IMPLICATIONS OF DOSE ESCALATION IN RADIATION THERAPY FOR CANCER TREATMENT.

Ismail Khaleel Alshabi[1]*, Ibrahim Khalil Ibrahim Alzaeb[2], Naif Mohammad Bawahab[3], Waleed Ayed Alqurashi[4], Talal Saleh Almatrafi[5], Awwad Audah Alsakhri[6], Abdulaziz Obaid Alotaibi[7]

ABSTRACT

Radiation doses can be escalated in radiation therapy, which has been identified as an innovative modality offering better treatment prospects by enabling delivery of higher doses of radiation only to tumor tissues with healthy tissues being spared, named conformity. Such a critical examination focuses on dose escalation in the field of cancer treatment through radiation therapy. It analyses its possible benefits, shortcomings, and influence on the outcomes of the treated patients. A critical reflection of the literature stems from a deep and thorough review that integrates the most important breakthroughs in the relevant areas, such as finding out how to choose a dose and avoiding adverse effects of medicines in long-term use of a therapy. The course of the analysis is also dedicated to new developments, up-to-date technologies, and further ways for dose-escalation in clinical practice, helping physicians not only with providing evidence-based treatment but also with decision-making.

Keywords: Dose escalation, radiation therapy, cancer treatment, tumor control, toxicity, patient outcomes.

[1]*Ministry of Health, Saudi Arabia, Email: Ialshabi@moh.gov.sa
[2]Ministry of Health, Saudi Arabia, Email: Ialzaeb@moh.gov.sa
[3]Ministry of Health, Saudi Arabia, Email: nmbawahab@moh.gov.sa
[4]Ministry of Health, Saudi Arabia, Email: WAALQURASHI@moh.gov.sa
[5]Ministry of Health, Saudi Arabia, Email: Taalmatrafi@moh.gov.sa
[6]Ministry of Health, Saudi Arabia, Email: aalskhri@moh.gov.sa
[7]Ministry of Health, Saudi Arabia, Email: aoalotaibi@moh.gov.sa

***Corresponding Author:** Ismail Khaleel Alshabi
*Ministry of Health, Saudi Arabia, Email: Ialshabi@moh.gov.sa

DOI: 10.53555/ecb/2022.11.8.127

INTRODUCTION

Radiotherapy usually applies to different types of curative, comforting, and adjuvant options depending on the cancer situation of the patient. In recent years, dose escalation has been a trendy principle, most commonly used to improve radiation therapy to increase the amount of radiation delivered to tumor tissues. Though the conventional approach of radiation doses is very effective in shrinking the tumor size and improving survival rates, this technique attempts to even further optimize the treatment efficacy by delivering more doses of radiation that target the tumor area while sparing healthy cells from damage. This article's critical review looks into the effects of dose escalation in radiotherapy as a treatment for cancer, focusing on tumor response, the toxicity of the treatment, and long-term survival rates. This research outcome will be based on a final analysis of the data collected from clinical studies and research experiments. It aims to shed light on the opportunities and limits of dose escalation strategies and help health specialists make treatment decisions for cancer patients (Myrehaug et.al 2022).

BODY

Clinical Efficacy of Dose Escalation:

The clinical doses of radiation therapy have been shown to positively correlate with the likelihood of tumor control and survival in various types of cancer, including prostate cancer, lung cancer, and head and neck cancer. A series of clinical studies have statistically proven that as the dose of radiation increases, local consolidation and progression-free survival can be improved, as indicated by these significant findings. Meta-analyses and systematic reviews have also provided a logo of imperviousness for the employment of dose escalation techniques in cancer outcomes enhancement across various cancer sites and stages of the disease. Consequently, it is possible to see patient-to-patient variability in the effectiveness of tumor features, patient conditions, and type of treatment (Barelkowski et., al 2020).

Figure 1: The relationship between radiotherapy and its effects on normal human



(Figura et. al 2020).

The dose-response correlation in the clinical studies shown in Figure 1 has two lines, one with greater tumor control after the lowest dose and the other with a higher frequency of tumors after the highest dose. Meta-analyses and systematic reviews have results that point out that, in terms of cancer sites and cancer stages, dose escalation strategies would improve treatment outcomes. "Radiation dose" analyses have proven to be significant in that respect, which has demonstrated the direct correlation between "radiation dose" and the response of tumors to radiation therapy as well as the survival of a patient. Therefore, the importance of optimizing radiation dosing strategies in clinical practice has been outlined (Krauss et. al 2023).

Nevertheless, each tumor may exhibit different response patterns to the dosing levels, and many factors may be considered, such as tumor characteristics, patient health, treatment methods, and others. Moreover, the escalation involves accounting for the gain against the possible escalation of treatment-associated toxicities and harm to normal tissues. Hence, customized treatment methods characterized by patient-specific features as well as tumor biology are paramount to ensure the vitality of the dose elevation strategies and increase the overall effectiveness of the treatment regimen without the risk of the inducement of side effects.

Generally, administering more doses during radiotherapy is one of the best treatment options that may be useful in significantly reducing the size of tumors and maximizing their survival rate. Through the utilization of more recent advancements in radiation delivery methods and radiotherapy planning technologies, healthcare professionals can personalize patient-based radiation dosing plans and target tumor features to achieve the best therapeutic outcomes as well as improve patients' quality of life (Krauss et. al 2023).

Toxicity Profiles and Treatment Tolerability

Cautious application of dose escalation helps in optimum tumor control, though it may pose a risk of toxicity and adverse effects on normal cells as well. The main sports late and near toxicities connected with radiation dermatitis, microsites, and gastrointestinal complications, which are frequent in patients with increased radiation dose; secondly, the dose escalation may further worsen the existing severe comorbidities and compromise the functioning of the organs, which will cause the treatment to be interrupted or the dose to be reduced. Patient selection, treatment plan techniques, and schedules of dose fractionation will all play a critical role in achieving the minor treatment toxicity and the best tolerability (Matsumoto et. al 2021. With sophisticated radiation-sending techniques like intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), prescription radiation dosages will be delivered to targets very thoroughly. A clinician will achieve this by minimizing the organ at risk, which is aimed at reducing the probability as well as the severity of treatment-related side effects.

Figure 2: The Repeated Shortcomings in Acute and Chronic Adverse Effects in Radiotherapy



(Matsumoto et. al 2021)

Figure 2 presents a schematic demonstration of the toxicity problems patients' face when applying escalated radiation doses, highlighting the most common adverse effects that occur during or after treatment. These toxicities could be a significant cause of a patient's impaired quality of life, and it may be necessary to use interventions to manage the symptoms and extend the treatment breakage periods.

Long-term outcomes and survival benefits:

The predicted late effects and improved survival ratio, however, are the most determinant factors in evaluating the effectiveness of escalated radiation therapy for cancer therapy. Long-term disorders with an extended period of tracking have been beneficial in realizing the product performance of the treatment and the patient's patient's life span as well as quality of life. Even 15 years following the delivery of dose-escalated radiation therapy, the trend of reduced local failures has maintained its course. The purpose of dose escalation is to increase radiation doses more intensely applied to the tumor target area, to remove any remaining cancer cells as much as possible, and to eliminate the chances of local recurrence. Hence, higher chronic disease-free survival is achieved in the long term by the chances of disease spreading and progression, which are particularly aggressive in biology and high-risk in cancer (Köthe et. al 2021). In addition, evidence suggests that higher doses are capable of elongating the long-term effects of specific cancers, namely prostate, head, and neck types. One example is prostate cancer, where an escalated dose of radiation therapy is more effective than a conventional dosage regimen. The outcome is a reduction in the risk of metastasis while increasing the survival rate. In the same way, in the case of head and neck cancer, dose escalation seems much more efficient than conventional radiotherapy; the locoregional control gets improved, resulting in better disease control due to the prolonged survival of cancer patients.

Through a dose of radiation therapy increasing intensity, patients with cancer can have the possibility of improving their survival chances by sparing them from salvage treatments and ameliorating symptoms of illness. One of the salient benefits of the maximum tolerance dose is that tumor control can be improved and the likelihood of disease recurrence can be reduced; therefore, the need for second-line treatments such as salvage surgery or systemic therapy, which have side effects and complications the patient may need to cope with, may be avoided. This may produce positive functional performance, a drop in side effects from the treatment, and general health with the addition of a relative quality of life for a cancer survivor.

Nevertheless, dosing escalation can optimize the patient outcome but should be balanced with the potential for treatment-related toxicity, where vulnerable patient populations could be vulnerable. Some patients, like the elderly or those with coexisting health conditions, may be more likely to develop treatment-related toxicity, such as damage caused by exposure to radiation and changes in the functioning of organs (Lee et. al 2023, April).

Finally, long-term follow-up studies have proven that patients keep improving in locoregional control, disease-free survival, and overall survival rates after five years and more after receiving dose-escalated radiotherapy compared with standard cancer therapies. However, regardless of whether dose escalation has the potential to support long-term survival and improved quality of life for patients who qualify, it should be emphasized that caution needs to be considered when making assessments that cover drug-related toxicity to ensure effective results with minimal negative response to the treatment.

Technological Advancements and Future Directions

The progress made with the latest technology has redefined radiation therapy and enabled dose escalation techniques that are tailored to treatment planning to maximize clinical benefit and minimize toxicities. IGRT, SBRT, and proton therapy, three critical breakthroughs in the world of radiotherapy, are now being used to boost dose intensification and lead to more precise and safer treatments.

Image-guided radiation therapy (IGRT) is a relatively new methodology that adopts imaging technologies, such as CBCT or PET, for precisely delineating targets and measuring anatomical changes in patients undergoing radiotherapy. Incorporating on-target real-time imaging treatment delivery is next-level guidance precision. It can adapt to microscopic deviations in tumor positions and target them, accounting for intrafractional motion and anatomical changes. Such possibility allows physicians to time-steadily step up radiation doses to tumor zones with sufficient certainty, bypassing critical nearby organs, hence diminishing the likelihood of treatment-related side effects.

SBRT utilizes state-of-the-art technology to generate highly conformal and sterilizing radiation doses aimed at extra cranial tissues, reaching sub millimeter precision. Typically, we achieve this with a significantly reduced number of treatment fractions. The SBRT stands out for targeting small tumors located in the lung, liver, spine, and prostate, which are the typical sites for cancer to spread. Unprecedented tumor control and fewer side effects can be achieved by the very steep dose gradients and advanced treatment planning algorithms for highly precise SBRT that limit radiation exposure to healthy tissues (Lin et. al 2020). This method makes it possible to apply a proper dose of lead, thereby resulting in high rates

of local tumor control and very successful treatment outcomes.

Proton-based therapy is the following technique that serves as a new way to escalate the dose during radiotherapy. Protons, rather than the radiation beams used in routine photon-based treatment, have distinct physical properties, and in particular, they allow tremendous dose deposition along with a low dose to the normal tissues, which translates into increased efficacy and fewer side effects. Proton therapy is a uniquely valuable option for any treatment that involves radiation exposure to regions near delicate organs or children, for whom sparing healthy tissues is of utmost importance. Through the utilization of the dose-shaping property of protons that can focus on the tumor being treated and deliver the prescribed dose with minor collateral damage, proton therapy delivers a high dose of radiation while causing minimal side effects, which offers the potential for the cure of tumors with decreased long-term complications.

A further push for development is represented not only by the technical improvements for treatment delivery but also through exertions to find out the more innovative treatment strategies that increase the therapeutic ratio of radiation. Radiation therapy boasts radiobiological optimization strategies that are designed to fully utilize the differences that exist between normal and tumor cell responses to enhance tumor cell killing while limiting healthy tissue damage. Through immunomodulation methods, applicants aim to make their immune system produce antifungals against tumors to increase treatment efficiency and improve outcomes. Two types of radiation, including molecularly targeted agents or immunotherapy, can be added as an additive approach to the previous radiation treatment based on their background of sensitizing tumors to radiation or modulating the tumor microenvironment (Mazzarotto et. al 2020).

In particular, various breakthroughs in machine learning and penetrating a deeper understanding of biology provide significant opportunities for enhancing adaptive radiation therapy and ensuring positive outcomes for cancer patients. With the use of up-to-date technologies and innovative treatment techniques, doctors aim at improving the battle against cancer and, thus, optimizing a patient's balance between tumor control and detrimental effects, which ultimately results in the patient's enhanced survival and better quality of life.

CONCLUSION

The progressive drag-up in radiation therapy carries the potential to be a significant factor in the enhancement of treatment effects for cancer, particularly by assisting to minimize the treatment toxicity so that a more substantial portion of the tumor is eliminated. The case of dose escalation treatment has been shown to work efficiently in terms of local control rates, which are extended along with progression-free survival. This treatment may lead to long-term survival for cancer patients (Zeng et. al 2023). Despite this, a challenge exists between the efficacy of dose escalation and the risks of toxicities, which are usually encountered in people with a risk of experiencing adverse effects. Individual approaches to radiation therapy and innovative radiation updates enable the application of dose escalation strategies and enhance the effectiveness of disease treatment, all while carefully minimizing treatment-related morbidity. Looking ahead, interdisciplinary collaboration, current research activities, and innovative therapy application will become the main directions of progress in radiation therapy at prescribed doses, cancer treatment, and cancer treatment.

RECOMMENDATION

The analysis's findings suggest several recommendations for enhancing dose escalation strategies in radiation therapy for cancer treatment:

The analysis's findings suggest several recommendations for enhancing dose escalation strategies in radiation therapy for cancer treatment.

- Personalized Treatment Planning

Indiscriminate treatment planning based on patient traits, tumor genetics, and therapy aims to boost the dosage-escalating process as much as toxicity can be reduced.

- Advanced Radiation Delivery Techniques

As the technology evolves and the radiation delivery methods get more advanced and globally accepted by the IMRT, VMAT, and SBRT, it is possible to perform dose escalation without affecting the nearby organs and minimize treatment-related toxicity.

- Multidisciplinary Collaboration

Encourage collaboration between radiation oncologists, medical physicists, dosimetrists, healthcare providers, etc., to develop high-dose plans and optimize methods for the positive and better results of cancer treatment.

- Long-Term Follow-Up

Develop thorough, protracted follow-up practices to measure the treatment outcomes, including treatment toxicities, and dwell on the benefits of life extension due to escalated dosages of radiation therapy.

- Research and Innovation

Enhance research and cutting-edge technology in radiation treatment, biology, and treatment strategies to leverage the therapeutic benefit of ramped-up, dosed radiation therapy while improving the overall outcome of cancer treatment (Atwell et. al 2020).

REFERENCE

1. Atwell, D., Elks, J., Cahill, K., Hearn, N., Vignarajah, D., Lagopoulos, J., & Min, M. (2020). A review of modern radiation therapy dose escalation in locally advanced head and neck cancer. *Clinical Oncology*, *32*(5), 330-341. https://www.sciencedirect.com/science/article/pii/S0936655519305345
2. Meduri, B., Gregucci, F., D'Angelo, E., Alitto, A. R., Ciurlia, E., Desideri, I., ... & AIRO Giovani-Italian Association of Radiation Oncology-Young Members. (2020). Volume de-escalation in radiation therapy: state of the art and new perspectives. *Journal of Cancer Research and Clinical Oncology*, *146*, 909-924. https://link.springer.com/article/10.1007/s00432-020-03152-7
3. Laskar, S., Sinha, S., Chatterjee, A., Khanna, N., Manjali, J. J., Puri, A., ... & Kurkure, P. (2022). Radiation therapy dose escalation in unresectable Ewing sarcoma: Final results of a phase 3 randomized controlled trial. *International Journal of Radiation Oncology* Biology* Physics*, *113*(5), 996-1002. https://www.sciencedirect.com/science/article/pii/S0360301622003376
4. Sher, D. J., Pham, N. L., Shah, J. L., Sen, N., Williams, K. A., Subramaniam, R. M., ... & Khan, S. M. (2021). Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer. *International Journal of Radiation Oncology* Biology* Physics*, *109*(4), 932-940. https://www.sciencedirect.com/science/article/pii/S0360301620344461
5. Hearn, N., Atwell, D., Cahill, K., Elks, J., Vignarajah, D., Lagopoulos, J., & Min, M. (2021). Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: a systematic review and meta-analysis of modern treatment approaches and outcomes. *Clinical Oncology*, *33*(1), e1-e14. https://www.sciencedirect.com/science/article/pii/S0936655520302429
6. Hall, W. A., Deshmukh, S., Bruner, D. W., Michalski, J. M., Purdy, J. A., Bosch, W., ... & Movsas, B. (2022). Quality of life implications of dose-escalated external beam radiation for localized prostate cancer: Results of a prospective randomized phase 3 clinical trial, NRG/RTOG 0126. *International Journal of Radiation Oncology* Biology* Physics*, *112*(1), 83-92. https://www.sciencedirect.com/science/article/pii/S0360301621008737
7. Zeng, K. L., Abugarib, A., Soliman, H., Myrehaug, S., Husain, Z. A., Detsky, J., ... & Tseng, C. L. (2023). Dose-escalated 2-fraction spine stereotactic body radiation therapy: 28 Gy versus 24 Gy in 2 daily fractions. *International Journal of Radiation Oncology* Biology* Physics*, *115*(3), 686-695. https://www.sciencedirect.com/science/article/pii/S0360301622034010
8. Koay, E. J., Hanania, A. N., Hall, W. A., Taniguchi, C. M., Rebueno, N., Myrehaug, S., ... & Erickson, B. (2020). Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach. *Practical radiation oncology*, *10*(6), e495-e507. https://www.sciencedirect.com/science/article/pii/S1879850020300357
9. Kepka, L., & Socha, J. (2021). Dose and fractionation schedules in radiotherapy for non-small cell lung cancer. *Translational Lung Cancer Research*, *10*(4), 1969. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107746/
10. Lin, F. C., Chang, W. L., Chiang, N. J., Lin, M. Y., Chung, T. J., Pao, T. H., ... & Sheu, B. S. (2020). Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy. *PloS one*, *15*(8), e0237114. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237114
11. Mazzarotto, R., Simoni, N., Guariglia, S., Rossi, G., Micera, R., De Robertis, R., ... & Bassi, C. (2020). Dosimetric feasibility study of dose escalated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC) patients: It is time to raise the bar. *Frontiers in Oncology*, *10*, 600940. https://www.frontiersin.org/articles/10.3389/fonc.2020.600940/full
12. Lee, S. L., Bassetti, M. F., & Rusthoven, C. G. (2023, April). The role of stereotactic body radiation therapy in the management of liver metastases. In *Seminars in Radiation*

Oncology (Vol. 33, No. 2, pp. 181-192). WB Saunders. https://www.sciencedirect.com/science/article/pii/S1053429622000807

13. Figura, N. B., Oliver, D. E., Mohammadi, H., Martinez, K., Grass, G. D., Hoffe, S. E., ... & Frakes, J. M. (2020). Novel dose escalation approaches for stereotactic body radiotherapy to adrenal oligometastases: A single-institution experience. *American Journal of Clinical Oncology*, *43*(2), 107-114. https://journals.lww.com/amjclinicaloncology/fulltext/2020/02000/Novel_Dose_Escalation_Approaches_for_Stereotactic.6.aspx
14. Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., ... & Gupta, G. P. (2020). Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists. *International Journal of Radiation Oncology* Biology* Physics*, *108*(1), 227-241. https://www.sciencedirect.com/science/article/pii/S0360301620311354
15. Köthe, A., Bizzocchi, N., Safai, S., Lomax, A. J., Weber, D. C., & Fattori, G. (2021). Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancer. *Radiation Oncology*, *16*, 1-10. https://link.springer.com/article/10.1186/s13014-021-01914-2
16. Matsumoto, Y., Fukumitsu, N., Ishikawa, H., Nakai, K., & Sakurai, H. (2021). A critical review of radiation therapy: from particle beam therapy (proton, carbon, and BNCT) to beyond. *Journal of personalized medicine*, *11*(8), 825. https://www.mdpi.com/2075-4426/11/8/825
17. Krauss, D. J., Karrison, T., Martinez, A. A., Morton, G., Yan, D., Bruner, D. W., ... & Sandler, H. M. (2023). Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial. *Journal of Clinical Oncology*, *41*(17), 3203-3216. https://www.ingentaconnect.com/content/wk/jco/2023/00000041/00000017/art00016
18. Barelkowski, T., Wust, P., Kaul, D., Zschaeck, S., Wlodarczyk, W., Budach, V., ... & Beck, M. (2020). Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. *Strahlentherapie und Onkologie*, *196*, 229-242. https://link.springer.com/article/10.1007/s00066-019-01562-2
19. Chow, R., Kang, M., Wei, S., Choi, J. I., Press, R. H., Hasan, S., ... & Simone, C. B. (2021). FLASH radiation therapy: review of the literature and considerations for future research and proton therapy FLASH trials. *Appl Radiat Oncol*, *10*(2), 16-21. https://www.appliedradiationoncology.com/articles/flash-radiation-therapy-review-of-the-literature-and-considerations-for-future-research-and-proton-therapy-flash-trials
20. Woods, K., Chin, R. K., Cook, K. A., Sheng, K., Kishan, A. U., Hegde, J. V., ... & Cao, M. (2021). Automated non-coplanar VMAT for dose escalation in recurrent head and neck cancer patients. *Cancers*, *13*(8), 1910. https://www.mdpi.com/2072-6694/13/8/1910
21. Myrehaug, S., Hudson, J., Soliman, H., Ruschin, M., Tseng, C. L., Detsky, J., ... & Sahgal, A. (2022). Hypofractionated stereotactic radiation therapy for intact brain metastases in 5 daily fractions: Effect of dose on treatment response. *International Journal of Radiation Oncology* Biology* Physics*, *112*(2), 342-350. https://www.sciencedirect.com/science/article/pii/S036030162102784X
22. Cooke, S. A., de Ruysscher, D., Reymen, B., Lambrecht, M., Persson, G. F., Faivre-Finn, C., ... & Belderbos, J. S. (2023). 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. *Radiotherapy and Oncology*, *181*, 109492. https://www.sciencedirect.com/science/article/pii/S0167814023000300
23. Rahimi, A., Simmons, A., Kim, D. N., Leitch, M., Haas, J., Gu, X., ... & Timmerman, R. D. (2022). Preliminary results of multi-institutional phase 1 dose escalation trial using single-fraction stereotactic partial breast irradiation for early stage breast cancer. *International Journal of Radiation Oncology* Biology* Physics*, *112*(3), 663-670. https://www.sciencedirect.com/science/article/pii/S0360301621029163